microdosing glp-1 peptides for Fat Loss in a Cutting Phase Interview with Dr. Tyna Moore,

Phase 3 data from the ACHIEVE-3 trial reveals that the investigational compound orforglipron outperformed oral semaglutide in both glycaemic control and weight reduction

Gut Microbes 14:2110639

Microbial diversity and composition in six different gastrointestinal sites among participants undergoing upper gastrointestinal endoscopy in Henan, China

These findings suggest that persistent immunometabolic alterations can remain in viral patients long after viral clearance, suggesting that sustained activation of these pathways may contribute to PCS

A.HasegawaN.et al (2025a)

1) and the hyperglycemic clamp of 10 nmol/kg (Fig